Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Data Management for Nitrosamines Project

A German pharmaceutical company approached Zamann requesting support in Data Management for the Nitrosamines/NDSRI Project.

Challenges Faced

A detailed GAP analysis in Quality Management Systems is essential for identifying process deficiencies effectively.
  • Data Management: The Manufacturing company’s data on suppliers, and Drug Products is stored in different formats and locations—spreadsheets, email systems, and isolated databases—without a centralized or standardized system to manage it. Data Management was required as a starting point for the Nitrosamine Project as a central reference for all critical information about the drug product, ensuring consistency, regulatory compliance, and efficient project execution. Without it, data gaps and inconsistencies could lead to delays, quality issues, and regulatory risks.

Zamann Pharma Support’s Approach

  • Regulatory Compliance: The Master Data system played a crucial role in identifying drug products that need testing. It acts as a centralized repository for all critical information related to drug products, enabling streamlined decision-making, prioritization, and compliance with regulatory requirements.
  • Improved Documentation: Having centralized and comprehensive Master Data for Drug Products significantly enhanced documentation processes within the organization. All product-related data—such as formulations, testing requirements, manufacturing details, and regulatory approvals—was stored in a single Master Data repository. Automatic retrieval of accurate data reduced manual data entry errors in documents such as Certificates of Analysis (CoA), Batch Records, and Quality Records.
  • Risk Mitigation: Effective Master Data Handling can significantly reduce risks in various aspects of business operations, Master Data ensures that all product information—such as specifications, manufacturing processes, and batch records—aligns with regulatory standards (e.g., FDA, EMA, ICH).

Results Achieved

  • Regulatory Compliance: The client achieved full compliance with FDA 21 CFR Part 11, EU Annex 11, and WHO guidelines, significantly reducing the risk of audit findings related to audit trails.
  • Streamlined Processes: The newly implemented SOPs provided a structured and repeatable process for conducting periodic reviews, ensuring consistency across all systems.
  • Risk-Based Review Frequency: The risk assessment SOP allowed the client to prioritize critical systems and allocate resources efficiently, focusing on high-risk areas.
  • Empowered Staff: With comprehensive training and detailed procedures in place, the client’s teams gained the confidence and skills needed to manage the Audit Trail Periodic Review independently.
  • Enhanced Data Integrity: By identifying and addressing potential anomalies through periodic reviews, the client strengthened their data integrity framework, ensuring the reliability and traceability of their computerized systems.
Laboratory
GMP qualification and lifecycle validation activities including IQ, OQ, and PQ supporting inspection readiness in pharmaceutical manufacturing.
Services

Qualification and Validation for GMP Systems

Our team supports the planning, execution, and maintenance of qualification and validation activities, including IQ, OQ, and PQ, to keep GMP-regulated systems compliant and under control.

Read More

Contact Us

Need help? Don't hesitate to get in touch
Zamann pharma support is committed to protecting and respecting your privacy, and we’ll use your personal information to administer your account and to provide the products and services you requested from us.

FAQ

1. How do regulatory teams identify which drug products require nitrosamine testing when product data is scattered across multiple systems?

Teams centralize all product-related information into a unified master data repository. First, they consolidate supplier data, formulations, and manufacturing records from spreadsheets, emails, and legacy databases. Then, they apply structured filtering rules aligned with regulatory expectations. As a result, they quickly identify at-risk products and eliminate delays caused by fragmented or incomplete data sources.

The most reliable method is to implement a controlled master data system that automatically feeds validated product information into regulatory documents. In addition, systems standardize inputs for CoA, batch records, and quality reports. Therefore, teams eliminate manual re-entry errors and ensure consistency across all documentation. This significantly improves accuracy during inspections and regulatory reviews.

3. How does centralized master data improve regulatory risk control in nitrosamine impurity assessments?3. How does centralized master data improve regulatory risk control in nitrosamine impurity assessments?

Centralized master data strengthens risk control by ensuring that all product specifications, supplier inputs, and manufacturing parameters align with regulatory standards such as ICH and EMA expectations. Moreover, it enables structured risk-based prioritization of products requiring assessment. Consequently, organizations reduce compliance gaps and maintain a traceable, inspection-ready data environment throughout the project lifecycle.